“淋巴瘤患者全程管理項(xiàng)目”專家委員會(huì)在西安楊森制藥有限公司支持下正式成立， 來自全國淋巴瘤領(lǐng)域的27位權(quán)威專家獲聘。

"Lymphoma Comprehensive Care Project" expert committee sponsored by Xi'an Janssen Pharmaceutical Co., Ltd. was formally established, and 27 top hematologists were selected into the Distinguished experts' panel.

 

本項(xiàng)目由 北京市希思科臨床腫瘤學(xué)研究基金會(huì)（希思科基金會(huì)）發(fā)起，由中國臨床腫瘤學(xué)會(huì)（CSCO）抗淋巴瘤聯(lián)盟 負(fù)責(zé)主要工作，本次專家委員會(huì)上制定了 中國首個(gè)《中國淋巴瘤患者全程管理規(guī)范》 ，并將在全國進(jìn)行推廣和落地。

This project was initiated by the Beijing CSCO Clinical oncology Research Foundation (The CSCO Foundation), and the Chinese Society of Clinical oncology (CSCO) Anti-Lymphoma Alliance is responsible for the implementation. The expert committee reviewed the first "SOPs for the Lymphoma Patient Comprehensive Care" in China, and it will be promoted and implemented nationwide.

 

項(xiàng)目旨在推進(jìn)實(shí)施健康中國2030戰(zhàn)略，響應(yīng)衛(wèi)健委號召，進(jìn)一步提高淋巴瘤診療能力建設(shè)，實(shí)現(xiàn)淋巴瘤患者全程的、規(guī)范化的管理，推動(dòng)國內(nèi)淋巴瘤領(lǐng)域的學(xué)科發(fā)展，有效提升患者的治療依從性，切實(shí)造福更多淋巴瘤患者。

“隨著淋巴瘤領(lǐng)域新的治療方案、新的治療理念不斷推出，例如以伊布替尼為代表的口服靶向無化療方案在臨床的廣泛應(yīng)用，淋巴瘤患者生存期不斷延長，逐漸成為一種慢病，為患者的管理提出了新的課題。”中國臨床腫瘤學(xué)會(huì)(CSCO)監(jiān)事會(huì)監(jiān)事長馬軍教授講到。

中華醫(yī)學(xué)會(huì)血液學(xué)分會(huì)主任委員吳德沛教授表示，我國淋巴瘤患者治療依從性存在問題，很多患者無法完成規(guī)范化、足療程的治療，嚴(yán)重影響預(yù)期的治療效果。所以我們應(yīng)當(dāng)關(guān)注患者在不同疾病階段和治療過程中的不同需求，實(shí)施患者的全程管理。

 

“淋巴瘤患者的全程管理理念在國外有現(xiàn)成的經(jīng)驗(yàn)可以借鑒，例如“美國梅奧的患者導(dǎo)航員癌癥患者管理模式”和“英國麥克米倫癌癥支持”，特別是“患者導(dǎo)航員模式”非常值得借鑒，通過“淋巴瘤全程管理模式”在江蘇省人民醫(yī)院的試點(diǎn)結(jié)果來看，通過專員管理患者，患者堅(jiān)持隨訪比例達(dá)85%，患者的治療依從性明顯提高。”中國臨床腫瘤學(xué)會(huì)(CSCO)抗淋巴瘤聯(lián)盟副主任委員李建勇教授介紹。

北京市希思科臨床腫瘤學(xué)研究基金會(huì)副理事長、中國臨床腫瘤學(xué)會(huì)(CSCO)理事會(huì)副監(jiān)事長、中國臨床腫瘤學(xué)會(huì)（CSCO）抗淋巴瘤聯(lián)盟主任委員朱軍教授強(qiáng)調(diào)，在全程管理的專員、醫(yī)生和護(hù)士三個(gè)角色中，專員是當(dāng)中一個(gè)特別重要的環(huán)節(jié)，成為“醫(yī)護(hù)好幫手、患者好朋友”，可以說起到了一個(gè)穿針引線的作用，具有非常重要的地位，我們希望看到通過這個(gè)項(xiàng)目，能夠催生出一批“患者全程管理示范中心”的醫(yī)院典型，探索出符合中國國情的創(chuàng)新的患者全程管理模式，進(jìn)而在全國普及，發(fā)揚(yáng)光大，讓全國的淋巴瘤患者都能享受全程管理的服務(wù)。

 

在本次大會(huì)上，CSCO副秘書長趙東陸教授為專家們梳理了《中國淋巴瘤患者全程管理規(guī)范》的框架和主要內(nèi)容，項(xiàng)目專家組將首先制定針對惰性淋巴瘤患者的管理規(guī)范，未來還將推廣到其他淋巴瘤亞型，惠及更多患者。

（部分參會(huì)專家）

(Part of the experts)

 

“淋巴瘤患者全程管理項(xiàng)目”將通過 “樹標(biāo)準(zhǔn)、做培訓(xùn)、審醫(yī)院、評先進(jìn)” 四步走，通過集結(jié)政府、學(xué)會(huì)、專家、患者等各方力量，逐步在全國各大醫(yī)院落地以患者為中心的，“醫(yī)、護(hù)、患”診療一體化的患者全程管理模式。

據(jù)悉，2017年，西安楊森制藥有限公司上市了世界首創(chuàng)的BTK抑制劑伊布替尼，用于治療慢性淋巴細(xì)胞白血病、小淋巴細(xì)胞淋巴瘤、套細(xì)胞淋巴瘤以及華氏巨球蛋白血癥，同期中國初級衛(wèi)生保健基金會(huì)啟動(dòng)了“億迎新生淋巴瘤患者關(guān)愛項(xiàng)目”。

 

“億迎新生淋巴瘤患者關(guān)愛項(xiàng)目”致力于打造服務(wù)中國淋巴瘤患者的權(quán)威公益平臺(tái)，該平臺(tái)是集患者教育、線上咨詢、預(yù)后篩查、患者管理和隨訪4大功能為一體的綜合性平臺(tái)，平臺(tái)成立以來，發(fā)布患教內(nèi)容近千篇，組織患教活動(dòng)數(shù)百場，點(diǎn)擊量超10萬次，擁有活躍用戶超萬人，已成為受到廣大淋巴瘤患者廣泛認(rèn)可的，在淋巴瘤患者中影響力最大的公益平臺(tái)之一。

 

藥物只是疾病治療中的一環(huán)，如何給患者帶來最大獲益， 真正做到以“患者為中心”，西安楊森無疑走在了行業(yè)的前列， 筆者期待有更多的制藥公司能夠兌現(xiàn)回饋社會(huì)的承諾，努力貢獻(xiàn)社會(huì)價(jià)值，積極融入社區(qū)發(fā)展，履行企業(yè)公民義務(wù)，成為能夠被社會(huì)認(rèn)可和贊賞的企業(yè)。

 

附：“淋巴瘤患者全程管理項(xiàng)目”專家委員會(huì)名單 （排名不分先后）

 

 

Top MNC cooperated with CSCO to initiate the world-class cancer support model in China, driven by their belief that patients are waiting.

"Lymphoma Comprehensive Care Project" expert committee sponsored by Xi'an Janssen Pharmaceutical Co., Ltd. was formally established, and 27 top hematologists were selected into the Distinguished experts' panel.

This project was initiated by the Beijing CSCO Clinical oncology Research Foundation (The CSCO Foundation), and the Chinese Society of Clinical oncology (CSCO) Anti-Lymphoma Alliance is responsible for the main work.The expert committee reviewed the first "SOPs for the Lymphoma Patient Comprehensive Care" in China, and it will be promoted and implemented nationwide.

The project aims to promote the implementation of the Healthy China 2030 strategy, and respond to the call of the Health Commission, further improve the capacity building of lymphoma diagnosis and treatment, realize the full-course and standardized management of lymphoma patients, promote the development of the domestic lymphoma field, and effectively improve the treatment compliance of patients, which can effectively benefit more lymphoma patients.

 

"With the continuous introduction of new treatment options and new treatment concepts in the field of lymphoma,such as the more and more usage of oral targeted chemotherapy-free regimens represented by ibrutinib in practice, the survival time of lymphoma patients continues to extend and gradually becomes a kind of chronic disease presents a new topic for the management of patients," said Professor Jun MA, Chairman of the Supervisory Board of the Chinese Society of Clinical oncology (CSCO).

Professor Depei WU, Chairman of Chinese Society of Hematology, said that Chinese  lymphoma patients have poor treatment compliance, and many patients can not complete standard and full course of treatment, which seriously affects the expected treatment effect. Therefore, we should pay attention to the different needs of patients in different disease stages and treatment processes and implement comprehensive care of patients.

"The comprehensive care concept of lymphoma patients can be learned from the existing experience of western countries, such as the "Cancer patient Navigator model of the Mayo clinic the United States" and "Macmillan Cancer Support in the United Kingdom," especially the "patient navigator model." It is worth sharing the "Lymphoma Comprehensive Care Model" pilot results in Jiangsu Provincial Hospital. The navigator supports the patients. As a result, the patient adheres to the follow-up rate as high as 85%, and the patient's treatment compliance is significantly improved. "Professor Jianyong Li, Vice Chairman of the Chinese Society of Clinical oncology (CSCO) Anti-Lymphoma Alliance, introduced.

Professor Jun ZHU, Vice Chairman of Beijing CSCO Clinical oncology Research Foundation, Vice Chairman of Chinese Society of Clinical oncology (CSCO), and Chairman of the Anti-Lymphoma Alliance of the Chinese Society of Clinical oncology (CSCO) mentioned that among the three roles of the navigator, doctor, and nurse in the comprehensive care, the navigator is a critical role, becoming a "good helper of medical staff and a good friend of patients," which played a critical role of the bridge patients and medical care. We hope that through this project, many hospital models of "patient comprehensive care demonstration centers" can be spawned, and innovative patient comprehensive care models that meet China's domestic conditions can be explored and then popularized and carried forward throughout China so that lymphoma patients in China can enjoy comprehensive care services. 

At this meeting, Professor Donglu ZHAO, CSCO Deputy Secretary-General, sorted out the framework and the detailed content of the "SOPs of Lymphoma Patient Comprehensive Care." The expert group of this project will first formulate management practices for indolent lymphoma patients. In the future, it will be extended to other lymphoma subtypes, benefiting more patients.

The implementation plan of the Lymphoma Comprehensive Care Project has four steps: standards setting, training, hospital accreditation, and best case sharing. Through the cooperation of government, academic groups, doctors, and patients, we hope this project will implement the lymphoma patient-centered integrated care model across China.

It is reported that in 2017, Xi'an Janssen Pharmaceutical Co., Ltd. put the world's first BTK inhibitor ibrutinib launched for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. At the same time, the China Primary Health Care Foundation launched the "iFuture Lymphoma Patient Care center."

"iFuture Lymphoma Patient Care center" is committed to building an trusted patient service platform for Chinese lymphoma patients. This platform is a comprehensive platform integrating patient education, online consultation, prognosis screening, patient management, and follow-up. Since the establishment of the platform, it has published nearly a thousand articles on patient education, organized hundreds of events on patient education, with more than 100,000 hits and more than 10,000 active users. It has become one of the public welfare platforms widely recognized by the majority of lymphoma patients and one of the most influential platforms in lymphoma patients.

Drugs are only one part of disease treatment. To bring the most significant benefit to patients and truly "patient-centered," Xi'an Janssen is undoubtedly at the forefront. The author hopes that more pharmaceutical companies will give back to society, strive to contribute social value, actively participate in community development, fulfill corporate citizenship obligations, and become a company that can be recognized and appreciated by society.